Perindopril protects against streptozotocin-induced hyperglycemic myocardial damage/alterations

Human and Experimental Toxicology

Volumn 31, Issue 11, 2012, Pages 1132-1143

  Patel, B M ^a   Agarwal, S S ^a   Bhadada, S V ^a  

^a NIRMA UNIVERSITY   (India)

Author keywords

cardiac hypertrophy; ISO; Perindopril; type 2 diabetes mellitus

Indexed keywords

C REACTIVE PROTEIN; CREATINE KINASE MB; ISOPRENALINE; LACTATE DEHYDROGENASE; PERINDOPRIL; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRADYCARDIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CHEMICAL PARAMETERS; CONTROLLED STUDY; DYSLIPIDEMIA; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE INJURY; HEART VENTRICLE HYPERTROPHY; HEMODYNAMIC PARAMETERS; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

ANIMALS; ANIMALS, NEWBORN; BLOOD GLUCOSE; CARDIOMEGALY; CARDIOTONIC AGENTS; DIABETES MELLITUS, EXPERIMENTAL; FEMALE; GLUTATHIONE; HEMODYNAMICS; LIPIDS; MALE; MALONDIALDEHYDE; OXIDATIVE STRESS; PERINDOPRIL; RATS; RATS, WISTAR;

RATTUS; RATTUS NORVEGICUS;

EID: 84869022946     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327112446817     Document Type: Article

References (71)

1. Anderson EA, Hoffman RP, Balon TW, Mark A. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest. 1991 ; 87: 2246-2252
2. Hypertension in Diabetes Study (HDS): 1. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens. 1993 ; 11: 309-317
3. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes. 1999 ; 48: 197-184
4. Helmy M. ADVANCE in management of vascular complications of diabetes. Lancet. 2007 ; 370: 829-840
5. Portha B, Levacher C, Picon L, Rosselin G. Diabetogenic effect of STZ in the rat during the perinatal period. Diabetes. 1974 ; 23: 889-895
6. Hsueh WA, Law RE. Cardiovascular risk continuum: implications of insulin resistance and diabetes. Am J Med. 1998 ; 105: 4-14
7. Tikellis C, Wookey PJ, Candido R, Andrikopoulos S, Thomas MC, Cooper ME. Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes. 2004 ; 53: 989-997
8. Ingelfinger JR, Solomon CG. Angiotensin- converting-enzyme inhibitors for impaired glucose tolerance-is there still hope?. N Engl J Med. 2006 ; 355: 1608-1610
9. Salmasi AM, Dancy M. Glucose intolerance: the hidden danger in hypertensives!. Int Angiol. 2005 ; 24: 207-214
10. Burnier M, Zanchi A. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens. 2006 ; 24: 11-25
11. Fressinaud P, Berrut G, Gallois H. Antihypertensive activity and acceptability based upon clinical and laboratory parameters of perindopril: chief results in 23,460 mild to moderate hypertension patients treated for 6 months in general practice (French). Ann Cardiol Angéiol. 1993 ; 42: 51-59
12. Suraniti S, Berrut G, Marre M, Fressinaud P. Antihypertensive efficacy and acceptability of perindopril in elderly hypertensive patients. Am J Cardiol. 1993 ; 71: 28E - 31E
13. Girerd X, Giannattasio C, Moulin C. Regression of radial artery wall hypertrophy and improvement of carotid artery compliance after long term antihypertensive treatment: the PERICLES study. J Am Coll Cardiol. 1998 ; 31: 1064-1073
14. Tropeano AI, Boutouyrie P, Pannier B. Brachial pressure-independent reduction in carotid stiffness after long term angiotensin converting enzyme inhibition in diabetic hypertensives. Hypertension. 2006 ; 48: 1-7
15. Thybo NK, Stephens N, Cooper A, Aalkjaer C. Efficacy of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension. 1995 ; 25: 474-481
16. Zhou M, Zhong HJ, Wu XY. Changes of ultrastructure and function of the aortic endothelium in streptozocin-diabetic rats and effect of perindopril. Bull Hunan Med Univ. 2001 ; 26: 41-44
17. Liu SK, Chen X, You JL, Zhou M. Protective effect of perindopril on dysfunction of endothelium- dependent relaxation in diabetic rats. Bull Hunan Med Univ. 2000 ; 25: 122-124
18. Toblli JE, Cao G, DeRosa G, Di Gennaro F. Angiotensin-converting enzyme inhibition and angiogenesis in myocardium of obese Zucker rats. Am J Hypertens. 2004 ; 17: 172-180
19. Rumble JR, Komers R, Cooper ME. Kinins or nitric oxide, or both, are involved in the antitrophic effects of angiotensin converting enzyme inhibitors on diabetes-associated mesenteric vascular hypertrophy in the rat. J Hypertens. 1996 ; 14: 601-607
20. Cooper ME, Cao Z, Rumble JR, Jandeleit K. Attenuation of diabetes-associated mesenteric vascular hypertrophy with perindopril: morphological and molecular biological studies. Metabolism. 1998 ; 47: 24-27
21. Goyal RK, Lakkad NB, Bangaru RA, Rao MV. Effects of chronic treatment with enalapril on STZ-induced diabetic rats. Pharmacol Res Commun. 1997 ; 9: 133-139
22. Moron MS, Depierre JW, Mannervik B. Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochim Biophys Acta. 1979 ; 528: 67-78
23. Slater TF, Sawyer BC. The stimulatory effects of carbon tetrachloride and other halogenoalkanes on peroxidative reactions in rat liver fractions in vitro. General features of the systems used. Biochem J. 1971 ; 123: 8
24. Siragy HM. ADVANCE in management of vascular complications of diabetes. Lancet. 2007 ; 370: 829-840
25. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1999 ; 354: 602
26. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in U.S. adults. J Am Med Assoc. 1999 ; 281: 1291-1297
27. Reaven GM, Chang H. Relationship between BP, plasma insulin and triglyceride concentration, and insulin action in spontaneously hypertensive rats and Wistar Kyoto rats. Am J Hypertension. 1991 ; 4: 34-38
28. Fogari R, Zoppi A, Lazzari P, Preti P. ACE inhibition but not Ang II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. J Cardiovas Pharmacol. 1998 ; 32: 616-620
29. Sjöholm A, Nyström T. Endothelial inflammation in insulin resistance. Lancet. 2005 ; 365: 610-612
30. Sharma AM, Janke J, Gorzelniak K, Engeli S. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension. 2002 ; 40: 609-611
31. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA. 2002 ; 288: 2981-2997
32. Taskinen M. Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus. Diabetes. 1992 ; 41: 12-17
33. Tesfamariam B, Brown ML, Cohen RA. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J Clin Invest. 1991 ; 87: 1643-1648
34. Hsueh WA, Anderson PW. Hypertension, the endothelial cell, and the vascular complications of diabetes mellitus. Hypertension. 1992 ; 20: 253-263
35. Laragh J. Review course. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens. 2001 ; 41: 84-89
36. Dzau VJ. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension. 2001 ; 37: 1047-1052
37. Li DY, Zhang YC, Philips MI, Sawamura T, Mehta JL. Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by Ang II type 1 receptor activation. Circ Res. 1999 ; 84: 1043-1049
38. Fennessy P, Campbell J, Mendelsohn F, Campbell G. Angiotensin-converting enzyme inhibitors and atherosclerosis: relevance of animal models to human disease. Clin Exp Pharmacol Physiol. 2007 ; 23: 30-32
39. Bhakdi S, Toprzewski M, Klouche M, Hemmes M. Complement and atherogenesis. Binding of CRP to degraded, nonoxidised LDL enhance complement activation. Arterioscler Thromb Vasc Biol. 1999 ; 19: 2348-2354
40. Pradhan A, Manson J, Rifai N, Buring JE, Ridker PM. Creactive protein, interleukin-6, and risk of developing type 2 diabetes mellitus. JAMA. 2001 ; 286: 327-334
41. Goyal BR, Parmar K, Goyal RK, Mehta AA. Beneficial role of telmisartan on cardiovascular complications associated with STZ-induced type-2 diabetic rats. Pharmacol Rep. 2011 ; 63 (4). 956-966
42. Brasier AR, Recinos A, Eledrisi MS. Vascular inflammation and the renin angiotensin system. Arterioscler Thromb Vasc Biol. 2002 ; 22: 1257-1266
43. Goyal BR, Mesariya P, Goyal RK, Mehta AA. Effect of telmisartan on cardiovascular complications associated with STZ- induced diabetic rats. Mol Cell Bioch. 2008 ; 314 (1-2). 123-131
44. Gohlke P, Kuwer I, Bartenbach S, Schnell A, Unger T. Effect of low-dose treatment with perindopril on cardiac function in stroke-prone spontaneously hypertensive rats: role of bradykinin. J Cardiovasc Pharmacol. 1994 ; 24: 462-469
45. Goyal BR, Patel MM, Bhadada SV. Comparative evaluation of spironolactone, atenolol, metoprolol, ramipril and perindopril on diabetes induced cardiovascular complications in type 1 diabetes in rats. Int J Diabetes Metab. 2011 ; 19 (1). 11-18
46. Grossman E, Shemesh J, Shamiss A, Thaler M, Carroll J, Rosenthal T. Left ventricular mass in diabetes-hypertension. Arch Intern Med. 1992 ; 152: 1001-1004
47. Guzik TJ, West NE, Black E, et al. Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res. 2000 ; 86: E85 - E90
48. Laursen JB, Rajagopalan S, Galis ZS. Role of superoxide in Ang II-induced but not catecholamine- induced hypertension. Circulation. 1997 ; 95: 588-593
49. Hefti MA, Harder BA, Eppenberger HM, Schaub MC. Signaling pathways in cardiac myocyte hypertrophy. J Mol Cell Cardiol. 1997 ; 9: 2873-2892
50. Cooper ME, Cao Z, Rumble JR, Jandeleit K, Allen TJ, Gilbert RE. Attenuation of diabetes-associated mesenteric vascular hypertrophy with perindopril: morphological and molecular biological studies. Metabolism. 1998 ; 47: 24-27
51. Wolff SR, Dean RT. Glucose autoxidation and protein modification. Biochem J. 1987 ; 245: 243-250
52. Low PA, Nickander KK. Oxygen free radical effects in sciatic nerve in experimental diabetes. Diabetes. 1991 ; 40: 873-877
53. Hermenegildo C, Raya A, Roma J, Romero FJ. Decreased glutathione peroxidase activity m sciatic nerve of alloxan-induced diabetic and its correlation with blood glucose levels. Neurochem Res. 1993 ; 18: 893-896
54. Warnholtz A, Nickenig G, Schulz E. Increased NADH oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation. 1999 ; 99: 2027-2033
55. Ghiadoni L, Magagna A, Versari D, et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension. 2003 ; 41: 1281-1286
56. Funakawa S, Okahara T, Imanishi M, Komori T, Yamamoto K, Tochino Y. Renin angiotensin system and prostacyclin biosynthesis in STZ diabetic rats. Eur J Pharmacol. 1983 ; 94: 27-33
57. Tooke JE, Goh KL. Endothelinopathy precedes type 2 diabetes. Diabetes Care. 1998 ; 12: 2047-2049
58. Miyata T, Taguchi T, Uehara M, et al. Bradykinin potentiates insulinstimulated glucose uptake and enhances insulin signal through the bradykinin B2 receptor in dog skeletal muscle and rat L6 myoblasts. Eur J Endocrinol. 1998 ; 138: 344-352
59. Dietze GJ, Wcklmayr M, Rett K, Jacob S, Henriksen EJ. Potential role of bradykinin in forearm muscle metabolism in humans. Diabetes. 1996 ; 45 (suppl 1). S110 - S114
60. Rett K, Wicklmayr M, Dietze GJ, Häring HU. Insulin-induced glucose transporter (GLUT1 and GLUT4) translocation in cardiac muscle tissue is mimicked by bradykinin. Diabetes. 1996 ; 45: S66 - S69
61. Campbell DJ, Kladis A, Duncan AM. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension. 1994 ; 23: 439-449
62. Effects of a perindopril-based BP lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur Heart J. 2003 ; 24: 475-484
63. Goyal RK, Rodrigues B, McNeill JH. Effects of tri-iodo-lthyronine on cardiac responses to adrenergic agonists in STZ-induced diabetic rats. Gen Pharmacol. 1987 ; 18: 357-362
64. Bhargava HN, Kasabdji D, Thompson EB. Subsensitivity to noradrenaline and ISO in rabbits acutely pre-treated with morphine. Gen Pharmacol. 1977 ; 8: 257-261
65. Baba T, Ishikawa T. Recent advances in pharmacological management of hypertension in diabetic patients with nephropathy. Effects of antihypertensive drugs on kidney function and insulin sensitivity. Drugs. 1992 ; 43: 464-489
66. Nordin C, Gilat E. Delayed after depolarisation and activity in ventricular muscle from rats in STZ induced diabetes. Circ Res. 1990 ; 57: 28-34
67. Denton RM, Randle RJ. Concentration of triglycerides and phospholipids in rat heart and gastronemics muscle effect of alloxan diabetes and perfusion. Bio Chem J. 1967 ; 104: 416-422
68. Oliveira DR, Santos RA, Santos GF, Khosla MC, Campagnole-Santos MJ. Changes in the baroreflex control of heart rate produced by central infusion of selective angiotensin antagonists in hypertensive rats. Hypertension. 1996 ; 27: 1284-1290
69. Loukianov E, Ji Y, Grupp IL, et al. Enhanced myocardial contractility and increased Ca21 transport function in transgenic hearts expressing the fast-twitch skeletal muscle sarcoplasmic reticulum Ca21-ATPase. Circ Res. 1998 ; 83: 889-897
70. Ganguly PK, Pierce GN, Dhalla KS, Dhalla NS. Defective sarcoplasmic reticular calcium transport in diabetic cardiomyopathy. Am J Physiol. 1983 ; 244: E528 - E535
71. Giacomelli F, Wiener J. Primary myocardial disease in the diabetic mouse: an ultrastructural study. Lab Invest. 1979 ; 40: 460-473